Biochemical Studies in Normal Pressure Hydrocephalus (NPH) Patients: Change in CSF Levels of Amyloid Precursor Protein (APP), Amyloid-beta (Aβ) Peptide and Phospho-tau

Overview

Journal J Psychiatr Res

Specialty Psychiatry

Date 2010 Sep 11

PMID 20828718

Citations 22

Authors

Balmiki Ray

Patricio F Reyes

Debomoy K Lahiri

Affiliations

Soon will be listed here.

Abstract

Normal Pressure Hydrocephalus (NPH) is one of the causes of dementia of the elderly characterized by impaired mental function, gait difficulties and urinary incontinence. Previously, it was proposed that some of the NPH patients may develop Alzheimer's disease (AD) like pathology. Aim of this study was to compare levels of different CSF biomarkers, including total secreted β-amyloid precursor protein (sAPP), sAPP-alpha form (sAPPα), amyloid-beta (Aβ) peptide, total-tau protein and hyperphosphorylated-tau protein in subjects from NPH and Non-NPH Control (NNC). CSF was collected from 23 NPH patients and 13 Non-NPH controls by lumber puncture. Western blot analysis was performed to measure levels of sAPP-total. ELISA was used separately to determine levels of sAPPα, Aβ peptide, total-tau and phospho-tau proteins. We found a significant decrease in levels of total secreted APP, sAPPα and Aβ (1-42) in the CSF sample of NPH patients vs. NNC. We did not observe any change in levels of total-tau or phospho-tau in NPH vs. NNC subjects. Notably, phospho-tau level was significantly increased in the NPH patients, who were suffering from the disease for more than one year, vs. NNC. Among five biomarkers studied, decreased sAPP, sAPPα and Aβ (1-42) levels in CSF can be molecular markers to distinguish NPH cases from NNC. Disease severity can also be assessed by increased levels of CSF phospho-tau protein and the ratio of phospho-tau to Aβ (1-42), which might be a useful tool for predicting conversion of NPH individuals to other neurodegenerative disorders including Alzheimer's disease (AD).

Citing Articles

Unbiased CSF Proteomics in Patients With Idiopathic Normal Pressure Hydrocephalus to Identify Molecular Signatures and Candidate Biomarkers.

de Geus M, Wu C, Dodge H, Leslie S, Wang W, Lam T Neurology. 2025; 104(5):e213375.

PMID: 39951680 PMC: 11837848. DOI: 10.1212/WNL.0000000000213375.

A bibliometric analysis and visualization of normal pressure hydrocephalus.

Chang T, Huang X, Zhang X, Li J, Bai W, Wang J Front Neurol. 2024; 15:1442493.

PMID: 39144708 PMC: 11322097. DOI: 10.3389/fneur.2024.1442493.

Alzheimer's Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus.

Pyrgelis E, Paraskevas G, Constantinides V, Boufidou F, Papaioannou M, Stefanis L Brain Sci. 2023; 13(11).

PMID: 38002553 PMC: 10670082. DOI: 10.3390/brainsci13111593.

Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review.

Pyrgelis E, Boufidou F, Constantinides V, Papaioannou M, Papageorgiou S, Stefanis L Diagnostics (Basel). 2022; 12(12).

PMID: 36552981 PMC: 9777226. DOI: 10.3390/diagnostics12122976.

Alzheimer's Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus.

Mazzeo S, Emiliani F, Bagnoli S, Padiglioni S, Del Re L, Giacomucci G J Pers Med. 2022; 12(6).

PMID: 35743720 PMC: 9225293. DOI: 10.3390/jpm12060935.

References

Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K . Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998; 357(2):299-309. DOI: 10.1006/abbi.1998.0813. View

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

Graff-Radford N . Normal pressure hydrocephalus. Neurol Clin. 2007; 25(3):809-32, vii-viii. DOI: 10.1016/j.ncl.2007.03.004. View

Iqbal K, Grundke-Iqbal I, Zaidi T, Merz P, Wen G, Shaikh S . Defective brain microtubule assembly in Alzheimer's disease. Lancet. 1986; 2(8504):421-6. DOI: 10.1016/s0140-6736(86)92134-3. View

Van Nostrand W, Wagner S, Shankle W, Farrow J, Dick M, Rozemuller J . Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992; 89(7):2551-5. PMC: 48699. DOI: 10.1073/pnas.89.7.2551. View

Wind A, Schellevis F, van Staveren G, Scholten R, Jonker C, van Eijk J . Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr Psychiatry. 1997; 12(1):101-8. DOI: 10.1002/(sici)1099-1166(199701)12:1<101::aid-gps469>3.0.co;2-r. View

Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M . Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem. 2006; 52(2):332-4. DOI: 10.1373/clinchem.2005.058776. View

Peskind E, Leverenz J, Farlow M, Ito R, Provow S, Siegel R . Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. Alzheimer Dis Assoc Disord. 1998; 11(4):201-6. View

Silverberg G, Mayo M, Saul T, Rubenstein E, McGuire D . Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003; 2(8):506-11. DOI: 10.1016/s1474-4422(03)00487-3. View

10.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

11.

Ray B, Bailey J, Sarkar S, Lahiri D . Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: Differential expression of neuronal and glial protein markers. J Neurosci Methods. 2009; 184(2):294-302. PMC: 2892104. DOI: 10.1016/j.jneumeth.2009.08.018. View

12.

Formichi P, Battisti C, Radi E, Federico A . Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol. 2006; 208(1):39-46. DOI: 10.1002/jcp.20602. View

13.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

14.

Pirttila T, Mehta P, Soininen H, Kim K, Heinonen O, Paljarvi L . Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Arch Neurol. 1996; 53(2):189-93. DOI: 10.1001/archneur.1996.00550020105022. View

15.

Adams R, Fisher C, Hakim S, Ojemann R, SWEET W . SYMPTOMATIC OCCULT HYDROCEPHALUS WITH "NORMAL" CEREBROSPINAL-FLUID PRESSURE. A TREATABLE SYNDROME. N Engl J Med. 1965; 273:117-26. DOI: 10.1056/NEJM196507152730301. View

16.

Holm A, Savolainen S, Alafuzoff I . Brain biopsy prior to treatment of Alzheimer's disease. Minim Invasive Neurosurg. 2003; 46(3):161-4. DOI: 10.1055/s-2003-40733. View

17.

Serot J, Bene M, Foliguet B, Faure G . Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol. 2000; 99(2):105-8. DOI: 10.1007/pl00007412. View

18.

Smach M, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S . Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol. 2009; 62(6):349-55. DOI: 10.1159/000241881. View

19.

Chakravarty A . Unifying concept for Alzheimer's disease, vascular dementia and normal pressure hydrocephalus - a hypothesis. Med Hypotheses. 2004; 63(5):827-33. DOI: 10.1016/j.mehy.2004.03.029. View

20.

Lins H, Wichart I, Bancher C, Wallesch C, Jellinger K, Rosler N . Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm (Vienna). 2004; 111(3):273-80. DOI: 10.1007/s00702-003-0075-x. View